



Supplementary Figure S2


a)








b)



c)





Supplementary Figure S3





Supplementary Figure S4



a)



b)




Supplementary Figure S5




Supplementary Figure S6


c)



n	Proteome		
	-	=	+
Immuno-peptidome	+	234	6
	-	1314	18
	+	8	18
	-	418	5




n	Proteome		
	-	=	+
Immuno-peptidome	+	696	43
	-	1203	25
	+	9	43
	-	199	4



n	Proteome		
	-	=	+
Immuno-peptidome	+	671	52
	-	1191	24
	+	17	52
	-	195	7

Supplementary Figure S6


a) HLA-A2⁺ subject stained with IAV-tetramer




Gating strategy


- 1) lymphocyte gate
- 2) exclusion of doublets
- 3) exclusion of dead cells
- 4) CD3+ cells
- 5) CD8+ IAV-tetramer+ cells of all CD3 cells
- 6) CD8+ IAV-tetramer+ cells of all CD8+ cells

b) HLA-A2⁺ subject no tetramer staining



c) HLA-A2⁻ subject stained with IAV-tetramer





Supplementary Figure S8